AbbVie Inc. — ABBV
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $221.89 | $392.16B | 168.1 | 15.6 | 36.7% | 8.7% | $6.92 3.1% | -148.4 |
Latest Headlines
- · Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
- · PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
- · Sector Update: Health Care Stocks Softer Late Afternoon
- · AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says
- · Sector Update: Health Care Stocks Decline Tuesday Afternoon
- · AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2021-12-31 | $56.2B | $11.5B | $6.53 | N/A | N/A | N/A |
| 1 | 2022-12-31 | $58.1B | $11.8B | $6.69 | 3.3% | 2.5% | 2.5% |
| 2 | 2023-12-31 | $54.3B | $4.9B | $2.75 | -6.4% | -58.9% | -58.8% |
| 3 | 2024-12-31 | $56.3B | $4.3B | $2.40 | 3.7% | -12.0% | -12.8% |
| 4 | TTM 2025-03-31 | $57.4B | $4.2B | $2.34 | 1.8% | -1.9% | -2.5% |
| 5 | Average | 0.6% | -17.6% | -17.9% |
EPS
Forecasts
Y/Y % Change
ABBV Year-over-Year Growth
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 3.3% | -6.4% | 3.7% | 8.2% | 10.2% | 3.8% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 7 | 7 | |
| EPS Growth (%) | 2.5% | -58.9% | -12.0% | 339.6% | 35.6% | 61.4% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 8 | 8 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $56.2B | $8.9B | $8.0B | $12.3B | $8.5B |
| 2022 | $58.1B | $8.9B | $6.5B | $15.3B | $8.5B |
| 2023 | $54.3B | $11.7B | $7.7B | $12.9B | $8.7B |
| 2024 | $56.3B | $8.5B | $12.8B | $14.8B | $8.4B |
| TTM | $59.6B | $9.8B | $13.3B | $14.0B | $8.3B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 3.30 | 0.25 | -19.09 | 23.57 | -0.63 |
| 2023 | -6.44 | 30.96 | 17.90 | -15.65 | 2.73 |
| 2024 | 3.71 | -27.30 | 66.66 | 14.61 | -3.59 |
| TTM | 5.88 | 14.98 | 3.91 | -5.30 | -1.57 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $137,182M |
| 1 | Cash | $6,467M |
| 2 | Total Liabilities | $137,320M |
| 3 | Total Debt | $70,481M |
| 4 | Total Equity | $-183M |
| 5 | Debt to Equity Ratio | -385.14 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $221.89 | 4.1% | FINVIZ Growth: 16% | Nicks: 7 Finviz: 31 |
Nick's: 0.000 | 6.6 | 168.1 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $1.32 EPS | TTM | $8.65 | -96.1% | $41.33 | -81.4% |
| $10.64 EPS | 2025 | $69.71 | -68.6% | $333.13 | 50.1% |
| $14.43 EPS | 2026 | $94.55 | -57.4% | $451.79 | 103.6% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 31.92% | 9.80% | 30.69% | 9.89% | 3.64% | 0.76% | 36.71% | 8.65% | 76.5% | 6.0% |
| 3 Years | 31.92% | 9.80% | 30.69% | 9.89% | 3.64% | 0.76% | 36.71% | 8.65% | 76.5% | 6.0% |
| 5 Years | 31.92% | 9.80% | 30.69% | 9.89% | 3.64% | 0.76% | 36.71% | 8.65% | 76.5% | 6.0% |
| 10 Years | 31.92% | 9.80% | 30.69% | 9.89% | 3.64% | 0.76% | 36.71% | 8.65% | 76.5% | 6.0% |